Search results for " Small Cell"
showing 10 items of 93 documents
Bcl-2, Bcl-xl, and pp32/PHAPI in resected non-small-cell lung cancer patients
2009
Einleitung: Fur viele Tumorarten ist der Einfluss des Apoptosesignalweges auf die Prognose der Tumorerkrankung beschrieben worden. So konnte fur die antiapoptotischen Proteine wie Bcl-2 und Bcl-xL gezeigt werden, dass sie den mitochondrialen Selbstzerstorungsmechanismus der Zellen herunterregulieren konnen. Fur nicht-kleinzellige Lungenkarzinomen (NSCLC) hingegen existieren widerspruchliche Angaben in der wissenschaftlichen Literatur in Bezug auf die prognostische Wertigkeit apoptotischer und insbesondere antiapoptotischer Faktoren. Ein weiterer wichtiger Faktor im genannten Mechanismus, welches NSCLC fur apoptotische Stimuli sensibilisieren soll, ist das Protein pp32/PHAPI. Fur bereits che…
Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?
2018
Chemotherapy with a platinum-based doublet has long been the cornerstone of the treatment for advanced non-small cell lung carcinoma (NSCLC) (1). Since the early 2000s, several driver gene mutations and translocations have been discovered, giving rise to the possibilities of targeted therapies (2-4).
Quelle place reste-t-il pour la chirurgie dans les cancers bronchiques de stade IIIA-N2 ?
2015
Resume Introduction Le cancer bronchique non a petites cellules (CBNPC) demeure un probleme de sante majeur, avec une survie globale a 5 ans des stades IIIA de l’ordre de 25 %. La prise en charge chirurgicale des CBNPC de stade IIIA demeure cependant controversee. Nous avons donc evalue les differentes strategies de prise en charge des CBNPC de stade IIIA-N2. Methodes De janvier 1990 a decembre 2013, les essais controles randomises evaluant la survie des patients traites par chimiotherapie d’induction suivie d’une resection chirurgicale vs chirurgie seule, et ceux evaluant la survie des patients traites par radio- ou chimiotherapie d’induction suivie d’une resection chirurgicale vs la combi…
MA04.03 Lung Tumorspheres Characterization Reveals Cancer Stem-Like Cells Potential Targets and Prognostic Markers in Non-Small Cell Lung Cancer
2019
Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?
2020
Abstract Introduction Non-small-cell lung cancer (NSCLC) is one of the most common and deadly cancers. Several molecular drivers of oncogene addiction are now known to be strong predictive biomarkers for target therapies. Advances in large Next Generation Sequencing (LNGS) have improved the ability to detect potentially targetable mutations. However, the integration of LNGS into clinical management in an individualized manner remains challenging. Methods In this single-center observational study we included all patients with advanced NSCLC who underwent LNGS. Somatic and germline exome analysis was performed with a restriction on 323 cancer related genes. Variants were classified and Molecu…
Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits l…
2002
Small cell lung cancer (SCLC) is usually classified into a two-stage system, limited (LD) and extensive disease (ED). However, the criteria for these two categories remain controversial. The widely used Veterans Administration Lung Study Group (VALG) definition of LD includes patients with primary tumor and nodal involvement limited to one hemithorax. In contrast, the International Association for the Study of Lung Cancer (IASLC) recommends that LD should additionally include all patients without distant metastasis. As a consequence, since treatment modalities for LD and ED could be different, individual clinical outcome of SCLC patients may be influenced by the staging system chosen. Among…